Терапевтически индуцированный нейроэндокринный рак предстательной железы

Терапевтически индуцированный нейроэндокринный рак предстательной железы (т-НЭРПЖ) относится к редким агрессивным формам заболевания, в основе которой заложен адаптивный ответ опухоли на стандартную андроген-депривационную терапию (АДТ). Несмотря на низкую частоту первичной диагностики, на долю т-НЭРПЖ, согласно данным крупных международных исследований, приходится до 30% случаев прогрессирования рака предстательной железы (РПЖ). Однако даже с учётом значительного роста числа публикаций в последние годы многие вопросы, касающиеся диагностики и лечения т-НЭРПЖ, остаются дискуссионными и требуют подтверждения в рамках крупных исследований. В данной статье представлен клинический случай т-НЭРПЖ, а также обобщены современные данные, посвящённые молекулярно-генетическим механизмам и ключевым сигнальным путям, лежащим в основе нейроэндокринной дифференцировки. Целью публикации служит расширение доказательной базы и углубление понимания клинических проявлений, диагностики и терапевтических стратегий при этом редком заболевании.

1. Рretl K. Zur Frage der Endokrinie der menschlichen vorsteherdrüse. Virchows Arch. path Anat. 1944;312:392–404. (In German). DOI: 10.1007/BF02655955

2. Kazzaz BA. Argentaffin and argyrophil cells in the prostate. J Pathol. 1974;112(3):189-193. DOI: 10.1002/path.1711120310

3. Ковченко Г.А., Сивков А.В., Каприн А.Д. Роль определения хромогранина А в лечении больных кастрационно-резистентным раком предстательной железы. Экспериментальная и клиническая урология. 2024;17(1):75-85. DOI: 10.29188/2222-8543-2024-17-1-75-85

4. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, Di Silverio F. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int. 2003;91(5):438-445. DOI: 10.1046/j.1464-410x.2003.03066.x

5. Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31(S1):S122-132. DOI: 10.1038/modpathol.2017.164

6. Weaver MG, Abdul-Karim FW, Srigley J, Bostwick DG, Ro JY, Ayala AG. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol. 1992;16(1):62-68. DOI: 10.1097/00000478-199201000-00009

7. di Sant’Agnese PA, De Mesy Jensen KL. Endocrine-paracrine cells of the prostate and prostatic urethra: an ultrastructural study. Hum Pathol. 1984;15(11):1034-1041. DOI: 10.1016/s0046-8177(84)80246-4

8. So JS, Gordetsky J, Epstein JI. Variant of prostatic adenocarcinoma with Paneth cell-like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5. Hum Pathol. 2014;45(12):2388-2393. DOI: 10.1016/j.humpath.2014.08.004

9. Patel GK, Chugh N, Tripathi M. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. Cancers (Basel). 2019;11(10):1405. DOI: 10.3390/cancers11101405

10. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6(4):503-519. DOI: 10.1677/erc.0.0060503

11. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol. 2000;31(4):406-414. Erratum in: Hum Pathol. 2000;31(6):778. DOI: 10.1053/hp.2000.7295

12. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018;36(24):2492-2503. DOI: 10.1200/JCO.2017.77.6880

13. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20(11):2846-2850. DOI: 10.1158/1078-0432.CCR-13-3309

14. Tucci M, Zichi C, Buttigliero C, Vignani F, Scagliotti GV, Di Maio M. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther. 2018;11:7353-7368. DOI: 10.2147/OTT.S153764

15. Vlachostergios PJ, Puca L, Beltran H. Emerging Variants of CastrationResistant Prostate Cancer. Curr Oncol Rep. 2017;19(5):32. DOI: 10.1007/s11912-017-0593-6

16. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271-286. DOI: 10.1038/nrurol.2018.22

17. Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C, Huang J. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. Mol Cancer Res. 2015;13(3):584-591. DOI: 10.1158/1541-7786.MCR-14-0277-T

18. McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021;27(13):3610-3619. DOI: 10.1158/1078-0432.CCR-20-4616

19. Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. Clin Cancer Res. 2018;24(4):927-938. DOI: 10.1158/1078-0432.CCR-17-0989

20. Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6:e27861. DOI: 10.7554/eLife.27861

21. Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J, Parker C. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol. 2015;67(4):673-679. DOI: 10.1016/j.eururo.2014.10.004

22. Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, Li M, Xu J, Zhang S, Ittmann M, Li W. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget. 2016;7(29):45171-45185. DOI: 10.18632/oncotarget.9359

23. Zhang Y, Zheng D, Zhou T, Song H, Hulsurkar M, Su N, Liu Y, Wang Z, Shao L, Ittmann M, Gleave M, Han H, Xu F, Liao W, Wang H, Li W. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat Commun. 2018;9(1):4080. DOI: 10.1038/s41467-018-06177-2

24. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871-874. Erratum in: Nature. 2007;446(7137):824. DOI: 10.1038/nature04431

25. Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol. 2013;10(7):405-413. DOI: 10.1038/nrurol.2013.110

26. Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, HessJ, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H. Deltalike protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484):eaav0891. DOI: 10.1126/scitranslmed.aav0891

27. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, Pennella A, Ventimiglia G, Barucci R, Piscazzi A, Prudovsky I, Landriscina M, Marchionni N, Tarantini F. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res. 2012;10(2):230-238. DOI: 10.1158/1541-7786.MCR-11-0296

28. Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019;10(1):278. DOI: 10.1038/s41467-018-08133-6

29. McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest. 2018;128(1):341-358. DOI: 10.1172/JCI93566

30. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305. DOI: 10.1038/nm.4045

31. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016;30(4):563-577. DOI: 10.1016/j.ccell.2016.09.005

32. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016;29(4):536-547. DOI: 10.1016/j.ccell.2016.03.001

33. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-495. DOI: 10.1158/2159-8290.CD-11-0130

34. Chen R, Dong X, Gleave M. Molecular model for neuroendocrine prostate cancer progression. BJU Int. 2018;122(4):560-570. DOI: 10.1111/bju.14207